Sanjivani Paranteral Secures Major Investment

Sanjivani Paranteral Limited (BSE: 531569), a pharmaceutical powerhouse, has given the nod for the issuance of 600,000 convertible warrants to promoter Ashwani Khemka, each priced at Rs 135.10, the company said in a press statement on Tuesday. Additionally, the company has approved the preferential allotment of 16,86,000 equity shares at Rs 135.10 per share, totalling Rs 22.77 crores, directed towards non-promoter investors. 

Notable investors in this initiative include India Bridge Fund (India Equity Fund1),  Ashish Kacholia, Monika Garware, Anurag Jain, and Ashika Global Securities.

This move is poised to set the stage for Sanjivani Paranteral's continued expansion and firm commitment to establishing itself as a leading force in the pharmaceutical landscape. The company's focus on advancing its position will be manifested through the development of a cutting-edge manufacturing facility, a collaboration with Hindustan Antibiotics . This facility is dedicated to the production of Intravenous (IV) formulations and IV sets, aligning with the industry's progressive technology and standards. A significant portion of the funding secured will be allocated to modernising existing facilities and fortifying infrastructure to meet the evolving demands of technology.

Srivardhan Khemka, Director of Sanjivani Parenteral, said, “This investment not only strengthens our collaboration with Hindustan Antibiotic but also underscores our unwavering dedication to shareholder value and healthcare. With the support of our investors, we are well-positioned for greater success and innovation in the pharmaceutical domain.”